Executive Summary
Option exercises across three contracts total $1,236,299,978 in obligations, with 1/3 defense-related (VA EHRM via Oracle) and the remainder civilian (GSA IT via Leidos and State construction via BL Harbert). Dominant theme is multi-year civilian IT delivery orders from GSA and VA, signaling backlog addition for Leidos Holdings (LDOS) and Oracle (ORCL) in stable federal tech services.
Highest-conviction bullish signal is Oracle's $518.96M VA EHRM award (materiality 8/10), providing ~$104M annual revenue potential through 2027 amid zero outlay to date. Leidos' $543.65M GSA IT order adds funded backlog nearing end-of-life in 2024, while BL Harbert's $173.69M State construction remains neutral with low materiality. Key risk is execution on unspent obligations ($0 outlay for Oracle and BL Harbert; negative for Leidos) and high firm-fixed-price risks on Oracle and BL Harbert contracts.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Contract Option Exercises digest from April 10, 2026.
Investment Signals (3)
- Leidos $543.6M GSA IT Delivery Order Bolsters Civilian Backlog (MEDIUM)▲
Leidos, Inc. (Leidos Holdings, Inc. subsidiary) secured $543.65M obligation (potential $729.6M with options) under cost-plus award fee via full and open competition for IT/telecom services through 2024, with $187.4M subawards across 1090 recipients signaling extensive network.
- Oracle $519M VA EHRM Order Signals Multi-Year IT Stability (HIGH)▲
Oracle Health Government Services awarded $518.96M firm-fixed-price delivery order (potential $632.8M with options) by VA for EHRM operations through 2027, not competed, with $12.46M subawards across 34 recipients and zero outlay to date.
- BL Harbert $173.7M State Construction Project Adds Long-Term Exposure (LOW)▲
BL Harbert International LLC received $173.69M firm-fixed-price contract via full and open competition for Podgorica Montenegro project through 2027, with $5.48M subawards across 47 recipients and zero outlay.
Risk Flags (2)
- Execution [HIGH RISK]▼
Leidos GSA contract shows negative total outlay of $-1.71M despite $543.65M obligation, while Oracle VA and BL Harbert State both at $0 outlay, signaling potential spending delays through 2024-2027 periods.
- Budget [MEDIUM RISK]▼
High contract risk (pricing) on Oracle $518.96M firm-fixed-price VA order and BL Harbert $173.69M State FFP contract, with unexercised options ($632.8M and matching potential).
Opportunities (2)
- ◆
Leidos GSA IT order potential upside to $729.6M via remaining options on mature delivery order.
- ◆
Oracle VA EHRM delivery order upside to $632.83M with options on 5-year IT services contract.
Sector Themes (1)
- ◆
Leidos $543.65M GSA and Oracle $518.96M VA awards under NAICS 541512 highlight large non-small business positioning in federal IT/telecom via cost-plus and firm-fixed-price vehicles, with significant subawards (34-1090 recipients).
Watch List (3)
- 👁
{"entity"=>"Leidos Holdings (LDOS)", "reason"=>"Track outlay progress from $-1.71M negative and option exercises to $729.6M potential on $543.65M GSA IT order.", "trigger"=>"outlay updates and 2024-02-29 end date"}
- 👁
{"entity"=>"Oracle (ORCL)", "reason"=>"$518.96M VA EHRM obligation at $0 outlay with $632.83M option potential.", "trigger"=>"option exercise and outlay start through 2027-04-10"}
- 👁
{"entity"=>"BL Harbert International LLC", "reason"=>"$173.69M State construction at $0 outlay through 2027-03-25.", "trigger"=>"outlay progress and subaward execution of $5.48M"}
Get daily alerts with 3 investment signals, 2 risk alerts, 2 opportunities and full AI analysis of all 3 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Contract Option Exercises
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals